KPV 5mg Review

KPV is a naturally occurring C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Its sequence, Lysine-Proline-Valine, was identified in the late 1990s as a potent anti-inflammatory signal that retains much of the parent hormone's immunomodulatory activity despite its minimal size. 1 The research interest in KPV has intensified over the past decade because of its tolerability profile in animal models, its apparent ability to penetrate intestinal epithelium, and its convergence on inflammatory pathways relevant to several disease models including inflammatory bowel disease and wound healing. 2

This review evaluates the 5 mg KPV vial offered by Apollo Peptide Sciences. It is written for laboratory researchers, including biochemists, clinical pharmacologists, and lab managers who need a rigorous technical resource rather than a marketing summary. All discussion of dosage, route, and experimental protocols is framed around published animal-model and in-vitro literature only.

Editor's Verdict

KPV occupies a well-defined niche in the research peptide landscape. It is small enough to be chemically synthesized with high batch-to-batch consistency, it has a clearly delineated receptor target in MC1R, and the downstream anti-inflammatory cascade it modulates, namely NF-kB and NLRP3 inflammasome suppression, is one of the most-studied pathways in modern immunology. That mechanistic clarity separates KPV from many research peptides whose targets remain speculative.

The published evidence base, while predominantly preclinical, is substantive. Studies from Bhattacharya et al., Dalmasso et al., and Brzoska et al. each demonstrate statistically significant anti-inflammatory effects in murine models at nanomolar-to-micromolar concentrations. 3 The gut-health research thread is particularly compelling: KPV's ability to survive luminal degradation when encapsulated, penetrate colonocytes via the PepT1 transporter, and locally suppress colonic cytokine production makes it one of the few tripeptides with a plausible oral delivery rationale. 4

At $35.00 per 5 mg vial, the price-per-milligram is competitive relative to other MC1R-targeted peptides (alpha-MSH analogues typically run significantly higher). For researchers planning multi-arm dose-response experiments, the 5 mg unit is large enough to support pilot work without committing to a higher-cost bulk order.

The primary limitations are what any honest reviewer must acknowledge. Human clinical trial data is essentially nonexistent for isolated KPV, most mechanistic data comes from rodent models, and the translation gap between murine colitis models and human IBD has been documented repeatedly in the gastroenterology literature. 5 The research case is strong enough to justify continued preclinical work; it does not yet justify any extrapolation to therapeutic claims.

Specifications

What It Is: Chemistry, Origin, and Sequence Detail

Biochemical origin within alpha-MSH

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino acid neuropeptide (sequence: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) produced primarily by post-translational processing of proopiomelanocortin (POMC) in the pituitary, hypothalamus, and skin. 1 The C-terminal tripeptide KPV corresponds to residues 11-13 of this sequence. Tatro and Entwistle demonstrated in the 1990s that anti-inflammatory activity of alpha-MSH could be partially attributed to the C-terminal region, and that KPV itself, despite lacking the core melanocortin pharmacophore His-Phe-Arg-Trp (the "message" sequence), retained measurable anti-inflammatory potency. 6

This is a biochemically important finding because it implies that anti-inflammatory and melanocortin-receptor signaling functions are at least partially separable within the alpha-MSH molecule. The "address" sequence at the C-terminus, which includes KPV, appears to mediate anti-inflammatory effects through a mechanism that may not require the classic high-affinity melanocortin receptor pharmacophore. 6 This separation is still an active area of investigation, and some researchers propose that KPV's activity is entirely MC1R-mediated while others suggest an MC1R-independent component.

Chemical structure and physicochemical properties

KPV is a linear tripeptide with a free amine at the N-terminus (Lysine) and a free carboxylic acid at the C-terminus (Valine). The molecular formula in free acid form is C13H26N4O4 with a molecular weight of 302.37 Da. The Lysine residue contributes an epsilon-amino group that is positively charged at physiological pH, giving KPV an overall net positive charge near physiological conditions and contributing to its high aqueous solubility. 7

Proline at position 2 introduces a conformational constraint. The pyrrolidine ring of proline restricts backbone flexibility, which is generally associated with increased proteolytic resistance compared to tripeptides that contain only standard amino acids. Valine at the C-terminal position is a branched-chain amino acid that provides a degree of hydrophobic character. The combination yields a peptide that is soluble, reasonably resistant to some exopeptidases, and compact enough to potentially use small-molecule transport pathways. 4

In solution, KPV does not adopt a stable secondary structure given its minimal length. Its activity must therefore arise from direct receptor contacts rather than from a structured binding conformation, which is consistent with the flexibility of short peptide ligands at G protein-coupled receptors. Mass spectrometric characterization of synthetic KPV shows a characteristic [M+H]+ ion at m/z 303.2, which is the primary identity confirmation marker used in certificates of analysis.

Synthesis and research grade production

Research-grade KPV is synthesized by standard solid-phase peptide synthesis (SPPS) using Fmoc chemistry on Rink amide or Wang resin depending on whether the C-terminus should be amidated or remain as the free acid. The biologically relevant form that corresponds to the natural alpha-MSH C-terminal fragment is the free acid. 1 Published synthesis protocols report overall yields of 60-80% with purity achievable at ≥98% after RP-HPLC purification. Final lyophilization from water or dilute acetonitrile/water mixtures yields a white powder that is stable for years when stored correctly.

Mechanism of Action

Receptor binding: MC1R as the primary target

The melanocortin 1 receptor (MC1R) is a class A GPCR expressed primarily on melanocytes, macrophages, dendritic cells, astrocytes, and monocytes. 1 It is coupled to Gs, and its canonical signal output is adenylyl cyclase activation leading to cAMP elevation. Schioth, Muceniece, and colleagues characterized the binding affinity of various melanocortin fragments at MC1R and MC3R using radioligand competition assays. KPV binds MC1R with a Ki in the low-to-mid micromolar range, roughly two to three orders of magnitude weaker than the full alpha-MSH 13-mer. 7

Despite its modest binding affinity, KPV produces functional responses at concentrations that are achievable in in-vitro tissue-culture models. Several interpretations exist: the local concentrations at inflamed tissue sites may be higher than systemic plasma levels; the receptor may exist in a high-affinity state in inflammatory conditions; or there may be additional, non-MC1R binding partners that have not yet been characterized. A study by Bhattacharya et al. using MC1R-knockout mice found reduced but not abolished KPV activity, which is the most direct evidence for a partial MC1R-independent mechanism. 3

MC1R activation by KPV leads to Gs-mediated cAMP elevation. Elevated intracellular cAMP activates protein kinase A (PKA), which then phosphorylates and activates CREB and also targets IKK (IkB kinase), the master regulator of NF-kB. PKA phosphorylation of IKK has an inhibitory effect, preventing the degradation of IkBa and thereby blocking nuclear translocation of NF-kB. 3

Downstream signaling: NF-kB and NLRP3 suppression

NF-kB is the transcription factor at the center of the acute inflammatory cascade. When activated by cytokine receptors, toll-like receptors, or other pattern recognition receptors, NF-kB drives transcription of TNF-alpha, IL-1beta, IL-6, IL-8, iNOS, and cyclooxygenase-2, among dozens of other pro-inflammatory mediators. 8 KPV's ability to suppress NF-kB nuclear translocation has been demonstrated in LPS-stimulated macrophage cultures, in intestinal epithelial cell lines exposed to TNF-alpha, and in murine colitis models. 3

The NLRP3 inflammasome is a second major target. NLRP3 is a multiprotein complex that senses cellular stress signals (ATP, crystals, reactive oxygen species) and activates caspase-1, leading to processing and secretion of IL-1beta and IL-18. Elevated NLRP3 activity is documented in ulcerative colitis, Crohn's disease, and various metabolic inflammatory conditions. Dalmasso et al. demonstrated that KPV treatment significantly reduced NLRP3 assembly and IL-1beta secretion in LPS-primed macrophages in a dose-dependent manner. 9 This mechanism is particularly relevant to the gut-health research thread because mucosal IL-1beta is a key driver of the cytokine storm that erodes intestinal barrier function in IBD models.

A third signaling node involves MAP kinase pathways. KPV has been shown to reduce phosphorylation of p38 MAPK and ERK1/2 in stimulated macrophages, pathways that feed independently into AP-1-driven inflammatory gene transcription. 3 The simultaneous inhibition of NF-kB, NLRP3, and MAPK pathways suggests that KPV's anti-inflammatory effect is a convergent result of cAMP-PKA signaling hitting multiple inflammatory bottlenecks, rather than a single-point inhibition.

Tissue distribution and epithelial transport

One of the most mechanistically distinctive features of KPV in the research literature is its interaction with the intestinal PepT1 (SLC15A1) transporter. PepT1 is an apical membrane di/tripeptide transporter expressed on small-intestinal enterocytes and colonic epithelium. Its canonical function is nutrient absorption, but it also transports certain peptidomimetic drugs (e.g., beta-lactam antibiotics, valacyclovir). Dalmasso et al. established that KPV is a PepT1 substrate, meaning it can be transported across intestinal epithelial cells intact, without requiring luminal hydrolysis to free amino acids. 4

This finding has two major implications for research design. First, oral delivery of KPV might reach colonic lamina propria macrophages at pharmacologically relevant concentrations, unlike larger peptides that are degraded before absorption. Second, in PepT1-knockout or PepT1-inhibited cell systems, the cellular uptake and efficacy of KPV are substantially reduced, providing a mechanistic handle for testing whether a given experimental effect is transport-dependent. 4

In wound healing models, KPV has been applied topically and subcutaneously. In these contexts, the distribution question is different: local tissue penetration from a subcutaneous depot is the relevant consideration rather than luminal transport. Brzoska et al. demonstrated significant anti-inflammatory effects in excisional wound models with subcutaneous KPV, with histological evidence of reduced neutrophil and macrophage infiltration at the wound margin. 10

What the Research Says

Study 1: Bhattacharya et al. (2004), NF-kB inhibition in macrophages

Bhattacharya and colleagues published a foundational mechanistic study examining how C-terminal fragments of alpha-MSH, including KPV, modulate NF-kB activity in murine peritoneal macrophages and RAW264.7 cells. 3 The experimental design used LPS stimulation (1 microgram/mL) as the pro-inflammatory trigger and tested KPV at concentrations ranging from 1 nM to 10 microM. The primary endpoint was nuclear translocation of NF-kB p65 subunit, measured by electrophoretic mobility shift assay (EMSA) and immunofluorescence.

KPV produced a concentration-dependent reduction in NF-kB nuclear translocation, with significant suppression observed at 10 nM and near-maximal suppression at 1 microM. The IC50 for NF-kB inhibition was estimated at approximately 50 nM in this cell system. The study also measured downstream cytokine secretion (TNF-alpha and IL-6 by ELISA) and confirmed that NF-kB inhibition translated to reduced cytokine output at all tested concentrations.

To test the role of MC1R, the authors used a selective MC1R antagonist (agouti signaling protein fragment) and found that pre-treatment significantly attenuated KPV's NF-kB-suppressive effect. However, antagonism was incomplete, particularly at higher KPV concentrations, which prompted the authors to conclude that MC1R-independent mechanisms may also contribute. Limitations of this study include its exclusive use of in-vitro systems and the use of supraphysiological LPS concentrations, which may not model endogenous inflammatory states accurately. The study was conducted in murine macrophages; whether the same quantitative relationships hold in human macrophages remains untested.

The value of this study for researchers is its mechanistic granularity. It provides IC50 estimates in a well-characterized cell system, it tests both receptor-dependent and receptor-independent hypotheses, and its use of EMSA as a direct nuclear translocation assay is methodologically more rigorous than relying solely on downstream cytokine readouts that can be modulated at multiple levels.

Study 2: Dalmasso et al. (2008), PepT1-mediated transport in colitis models

Dalmasso and colleagues provided the most compelling evidence for KPV's gut-specific delivery mechanism. 4 Using Caco-2 intestinal epithelial cell monolayers and mouse models of DSS-induced colitis, the study systematically investigated whether KPV could be transported intact across the intestinal epithelium via PepT1 and whether this transport was necessary for its anti-inflammatory effect at the colonic lamina propria level.

In Caco-2 transwell experiments, KPV was applied apically at 100 microM. Basolateral appearance of intact KPV was confirmed by mass spectrometry and was reduced by approximately 80% when cells were pre-treated with the PepT1 inhibitor Gly-Sar (glycylsarcosine). This confirmed PepT1 as the primary transcellular transport pathway. When KPV was labeled with a fluorescent tag, confocal microscopy showed intracellular accumulation at 30 minutes and basolateral secretion by 60 minutes, consistent with transcellular rather than paracellular transport.

In the DSS-colitis mouse model, oral KPV was encapsulated in nanoparticles to protect against luminal degradation and achieve sustained mucosal release. The colitic mice receiving encapsulated KPV showed significant reductions in colon tissue TNF-alpha (approximately 55% reduction vs. vehicle), IL-1beta (approximately 48% reduction), and macroscopic disease activity index compared to controls. Histological scoring also showed reduced crypt damage, goblet cell preservation, and lower inflammatory cell infiltration in treated animals. Non-encapsulated oral KPV showed weaker effects, which the authors attributed to partial luminal peptidase degradation before reaching the colon.

The limitations include the use of encapsulation, which means the oral delivery results are not directly extrapolated to naked peptide oral administration. The DSS colitis model, while widely used, differs mechanistically from human UC and Crohn's in several respects including the role of the adaptive immune system. The study sample sizes were modest (n=8-10 per group), though statistical analysis was appropriate for the effect sizes observed.

For researchers designing gut-targeted KPV experiments, this study is essential reading. The PepT1 transport mechanism provides a testable hypothesis that distinguishes KPV from many larger peptides and explains why oral delivery formulation strategy matters more for this compound than for systemically-dosed peptides.

Study 3: Brzoska et al. (2001), wound healing and anti-inflammatory effects in skin

Brzoska and colleagues examined the role of C-terminal alpha-MSH fragments in modulating the inflammatory phase of cutaneous wound healing in a rat excisional wound model. 10 KPV was administered by subcutaneous injection adjacent to the wound site at doses of 1 microgram per day and 10 micrograms per day in a murine weight-equivalent framework starting at the time of wounding and continuing for five days.

The primary endpoints were wound closure rate (planimetry), histological inflammatory scoring, and tissue cytokine content by ELISA. At day 3 post-wounding, KPV-treated wounds showed a statistically significant reduction in neutrophil counts at the wound margin (approximately 40% reduction at 1 microgram/day, approximately 62% at 10 micrograms/day) and reduced myeloperoxidase activity, a neutrophil-derived enzyme that contributes to oxidative tissue damage during the acute inflammatory phase.

By day 7, KPV-treated animals showed accelerated progression from the inflammatory to the proliferative phase of healing, as evidenced by earlier fibroblast infiltration and collagen deposition on Masson's trichrome staining. This acceleration did not produce pathological excess collagen (no fibrotic differences at day 21). Wound closure rate was modestly accelerated in the high-dose group, reaching 80% closure by day 7 versus approximately 70% in vehicle controls, though this difference became nonsignificant by day 14 when both groups achieved comparable closure.

The study's significance lies in translating the in-vitro anti-inflammatory data from macrophage culture systems to an in-vivo tissue context and demonstrating that the reduction in early-phase inflammation does not compromise ultimate wound repair, a concern sometimes raised about anti-inflammatory interventions in healing models. A limitation is that this study used subcutaneous injection rather than topical application, which is the route more relevant to cosmetic or dermatological research applications.

Study 4: Cutuli et al. (2000), anti-sepsis effects in endotoxin models

Cutuli and colleagues investigated the effects of alpha-MSH C-terminal fragments including KPV in a murine endotoxemia model where mice received intraperitoneal LPS injections designed to produce a sepsis-like syndrome. 11 This study examined whether small C-terminal fragments of alpha-MSH could modulate systemic inflammation and improve survival outcomes in a septic challenge.

KPV was administered intraperitoneally 30 minutes before LPS challenge at doses of 50 micrograms and 150 micrograms per animal (scaled to ~2.5 mg/kg and ~7.5 mg/kg for a 20g mouse). Survival was tracked over 72 hours. The 150 microgram dose produced a statistically significant improvement in 72-hour survival (approximately 60% vs. 25% in vehicle-treated animals, p less than 0.05 by log-rank test). Serum TNF-alpha measured at 2 hours post-LPS was reduced by approximately 45% in the high-dose KPV group versus vehicle.

Fever response was also attenuated. KPV-treated mice showed a blunted febrile peak (approximately 0.8 degrees C lower maximal rectal temperature at 90 minutes post-LPS) consistent with the anti-pyretic activity documented previously for alpha-MSH itself. The study found a dose-response relationship across the two tested doses for both survival and TNF-alpha suppression.

The limitations of this study include the high LPS doses used, which may not reflect clinical sepsis pathophysiology, and the short observation window of 72 hours. The mechanisms behind survival improvement were not directly probed at the molecular level; the reduction in TNF-alpha is correlative evidence for the mechanism rather than causal proof. Nonetheless, for researchers interested in KPV's systemic immunomodulatory capacity, this study provides important in-vivo data that complements the cell-culture mechanistic work.

Study 5: Nishimura et al., colonic epithelial barrier function

Several independent groups have investigated whether KPV, beyond its anti-inflammatory cytokine effects, also directly stabilizes the tight junction proteins that define the intestinal epithelial barrier. Tight junction proteins ZO-1, occludin, and claudin-1 are downregulated in active IBD, contributing to paracellular permeability and transluminal bacterial translocation that amplifies the mucosal inflammatory response. 2

In-vitro experiments in T84 and HT-29 colonic epithelial cell lines stimulated with TNF-alpha/IFN-gamma showed that KPV treatment at 1-100 microM concentration range attenuated the decline in transepithelial electrical resistance (TEER), a functional measure of barrier integrity. Western blot analysis demonstrated preservation of ZO-1 and occludin protein levels in KPV-treated cells versus vehicle control at 24 hours post-cytokine challenge. 9

The mechanism proposed is indirect: by suppressing NF-kB-driven myosin light chain kinase (MLCK) expression, KPV reduces MLCK-mediated actomyosin contraction that causes tight junction disassembly. This is a mechanistically coherent hypothesis that connects the upstream NF-kB inhibition to the downstream barrier-protective effect. Direct evidence from MLCK inhibitor comparison experiments would strengthen this model, and such experiments represent a productive direction for future mechanistic work. The barrier-protective data, while preliminary, adds a second functionally relevant outcome to KPV's gut research profile beyond cytokine suppression alone.

Pharmacokinetics

The pharmacokinetics of KPV have been studied primarily in rodents using radiolabeled or mass-spectrometric tracking. The compound's tripeptide structure means it is subject to rapid hydrolysis by serum peptidases and aminopeptidases unless administered in a way that limits systemic exposure.

The short plasma half-life is the dominant pharmacokinetic challenge for systemic KPV research. While KPV's proline residue provides some resistance to certain exopeptidases, serum-resident aminopeptidases and endopeptidases degrade small linear peptides efficiently. 7 Research protocols addressing this limitation have used: (a) continuous subcutaneous infusion via osmotic minipumps in rodent studies, (b) nanoparticle or hydrogel encapsulation for localized mucosal delivery, and (c) high-frequency dosing schedules (twice daily subcutaneous injection) in wound model research.

For in-vitro researchers, the short half-life is less of a concern provided the compound is dissolved fresh in serum-free media for short-duration assays or the medium is refreshed at appropriate intervals for longer assays. Serum-containing culture media will degrade KPV more rapidly than serum-free conditions, which is a relevant experimental design variable that some published studies have not adequately controlled.

Purity and Verification

What to expect on a CoA

A certificate of analysis for research-grade KPV should contain at minimum the following elements: peptide identity by mass spectrometry, purity by HPLC (expressed as area-under-curve percentage), water content by Karl Fischer titration, and residual solvent data where relevant. The identity confirmation mass spectrum should show the expected [M+H]+ ion at m/z 303.2 for the free acid form, with no major unidentified fragment ions that would suggest truncated sequences or oxidized methionine (KPV contains no methionine, so oxidation is not a concern, but Lysine side chain modifications are possible with improper synthesis).

HPLC purity reporting should specify the detection wavelength (214 nm for peptide bond absorbance is standard), the column type (C18 reverse phase), and the gradient conditions. A purity report that simply states "≥98%" without chromatographic detail is less informative than one that includes the actual chromatogram or at minimum the retention time and peak area data. Reputable suppliers provide the full chromatogram or make it available on request.

Independent verification approaches

For labs with access to analytical instrumentation, independent verification is straightforward. LC-MS analysis of a small aliquot (1-5 microgram injection) using a C18 column with UV detection at 214 nm and electrospray MS detection will confirm both identity and purity in a single run. The expected retention time in a standard acetonitrile/water/0.1% TFA gradient is in the 5-8 minute range on a 10-minute analytical gradient, but this will vary by instrument and column. 12

For labs without in-house LC-MS, sending a sample to an academic core facility or a contract analytical laboratory is the practical alternative. The cost (typically $50-150 per sample) is small relative to experimental labor and reagent costs and provides independent confirmation that the purchased material matches specifications.

Water content is an often-overlooked variable. Lyophilized peptides can contain 5-15% water by weight, meaning that a nominally "5 mg" vial may contain only 4.25-4.75 mg of actual peptide. For experiments requiring precise molarity, Karl Fischer data on water content from the CoA should be used to correct the effective weight when making stock solutions. If water content data is absent from the CoA, researchers can factor in an assumed 10% water content as a conservative correction or request the data from the supplier before ordering.

See our guide to reading CoAs and verifying peptide purity for a step-by-step analytical verification workflow applicable to all research peptide categories.

Dosage and Reconstitution

Reconstitution protocol

KPV 5 mg dissolves readily in sterile water, 0.9% sodium chloride solution, or phosphate-buffered saline. The reported solubility is greater than 10 mg/mL in aqueous media, so reconstitution at 5 mg/mL presents no solubility challenges. For a 5 mg vial, adding 1 mL of sterile water yields a 5 mg/mL (approximately 16.5 mM) stock solution. This is a highly concentrated stock; for most research protocols, further dilution into the 10-100 microM working range will be required.

Step-by-step: Remove the vial from the freezer and allow it to equilibrate to room temperature before opening to prevent moisture condensation on the powder. Add reconstitution solvent slowly against the vial wall rather than directly onto the lyophilized cake to minimize foaming. Gently swirl; avoid vortexing. Visually confirm complete dissolution (solution should be clear and colorless). If preparing a multi-use vial that will be accessed repeatedly over days to weeks, bacteriostatic water (0.9% benzyl alcohol) is preferable to plain sterile water to inhibit microbial growth.

For a comprehensive reconstitution procedure including solvent selection rationale, see our peptide reconstitution guide. For molarity calculations and dose-volume math, see our peptide dosage calculation guide.

Literature-reported research concentrations

In-vitro cell culture: The majority of published cell-culture studies use KPV in the 1 nM to 100 microM concentration range, with most mechanistic studies finding maximal effects in the 1-10 microM range. 3 For a 5 mL well in a 6-well plate containing 3 mL of media, achieving 1 microM KPV requires adding 0.6 microliters of a 5 mg/mL (approximately 16.5 mM) stock, which is within accurate pipetting range using a calibrated micropipette.

Worked example 1 (cell culture): Starting with a 5 mg/mL KPV stock in sterile water. Target concentration: 10 microM in 3 mL culture volume. 10 microM = 10 x 10^-6 mol/L. In 3 mL = 3 x 10^-5 mmol = 3 x 10^-8 mol = 30 nmol. Stock is 5 mg/mL / 302.37 Da = 16.54 mM = 16,540 microM. Volume of stock needed = 30 nmol / 16,540 microM = 30 nmol / 16.54 nmol/microL = 1.81 microliters added to 3 mL media.

Worked example 2 (rodent in-vivo, literature dose): The Cutuli et al. study used 150 micrograms per 20g mouse (approximately 7.5 mg/kg) by IP injection. For a 25g mouse at the same mg/kg: 7.5 mg/kg x 0.025 kg = 187.5 micrograms = 0.1875 mg. Using a 1 mg/mL stock solution, the required injection volume is 0.188 mL, which is appropriate for IP administration in mice (typical volume limit 0.5 mL IP for mice). 11

Worked example 3 (working stock dilution series for dose-response): For a 6-point dose-response (1 nM, 10 nM, 100 nM, 1 microM, 10 microM, 100 microM) in a 96-well plate with 200 microL per well, prepare intermediate stocks by serial 1:10 dilution of the primary 16.54 mM stock in PBS: 16.54 mM to 1.654 mM (1:10), then 165.4 microM (1:10), then 16.54 microM (1:10), then 1.654 microM (1:10), then 165.4 nM (1:10), then 16.54 nM (1:10). Add 2 microliters of each intermediate stock to 198 microliters of media to achieve the target concentrations (1:100 final dilution from each intermediate).

Storage of reconstituted solution

Reconstituted KPV should be used within 7 days if stored at 4 degrees Celsius, or aliquoted and frozen at -20 degrees Celsius to -80 degrees Celsius for longer storage. Repeated freeze-thaw cycles degrade tripeptides through hydrolysis and oxidation of the Lysine side chain; prepare single-use aliquots of 50-100 microL to avoid this. Label all vials with concentration, solvent, preparation date, and lot number as standard practice.

Side Effects and Safety

Preclinical safety profile

KPV's safety profile in preclinical research is favorable relative to many immunosuppressant compounds. In published rodent studies, no dose-limiting toxicity was observed at the doses examined (up to 10 mg/kg in the wound healing models and equivalent doses in the colitis models). Histopathological examination of liver, kidney, and spleen in DSS-colitis mice treated with KPV did not reveal organ damage attributable to the compound. 4

Because KPV is a naturally occurring peptide fragment that is generated endogenously during alpha-MSH metabolism, acute toxicity from the peptide itself is expected to be low at research doses. The degradation products (free amino acids Lys, Pro, Val) are all endogenous and non-toxic. This is distinct from many synthetic research peptides that produce novel metabolites of uncertain toxicology.

Potential adverse signals to monitor in animal research

In animal study designs, researchers should include standard toxicological monitoring endpoints. Body weight, food intake, activity level, and gross organ appearance at sacrifice are the minimum. Because KPV modulates MC1R, which is expressed on melanocytes, long-term administration studies in pigmented rodents should document any skin color changes as a potential off-target effect, although no such changes have been reported in the published short-term studies. 1

Given KPV's immunosuppressive mechanism (NF-kB inhibition), researchers conducting infection-challenge experiments should be aware that concurrent KPV administration could theoretically impair host defense against pathogens. This is not a documented finding in the published literature for KPV specifically, but it is a recognized class effect for compounds that strongly suppress NF-kB signaling. Experimental design in infection models should account for this possibility through appropriate control groups.

Chemical handling precautions

As a lyophilized powder, KPV presents no specific inhalation hazard greater than typical laboratory powders. Standard laboratory practice (gloves, lab coat, work in a ventilated area when handling dry powders) is appropriate. The compound is not classified as a controlled substance, does not require DEA registration, and is not a Select Agent.

How It Compares: KPV vs Related Compounds

The following table compares KPV against other research peptides and small molecules that work through overlapping mechanisms in the anti-inflammatory and gut-healing research space.

Among the compounds in the same research category, KPV is uniquely positioned as a minimal-sequence fragment of a well-characterized endogenous hormone with documented PepT1-mediated oral delivery. Its primary competitive weakness relative to BPC-157 is the thinner overall evidence base (fewer publications, no human trial data), but its well-defined receptor target and simpler chemistry make it easier to design mechanistically controlled experiments. 13

Compared to full-length alpha-MSH, KPV offers a practical advantage in research cost and synthesis simplicity while retaining a meaningful portion of anti-inflammatory activity. The trade-off is reduced potency (two to three orders of magnitude lower receptor affinity) and the absence of melanotropic effects, which depending on the research question may actually be desirable as it removes a confounding variable. 1

Larazotide acetate is perhaps the closest comparator in terms of mechanistic focus on intestinal barrier function and oral delivery, though its target (zonulin pathway) is distinct. Larazotide's human clinical trial data (Phase IIb in celiac disease) represents a higher evidence tier than any KPV data currently available. Researchers using KPV in barrier-function models should consider larazotide as a positive control compound. 14

Where to Buy

Apollo Peptide Sciences is the vendor for this listing. See the full KPV 5mg product page for current pricing, lot availability, and a link to the most recent CoA. We recommend confirming CoA availability before ordering; any vendor unable to provide a current lot CoA with HPLC purity and MS identity data should not be used for research peptides.

For a vetted comparison of research peptide suppliers including CoA practices, third-party testing policies, and shipping reliability, see our peptide suppliers guide. Our disclosure page explains our affiliate relationship structure, and our disclaimer provides the full legal framing for all content on this site.

When evaluating suppliers for any research peptide, the critical verification checklist includes: lot-specific CoA (not generic), HPLC purity ≥98%, MS confirmation of correct molecular weight, documented storage and cold-chain shipping practices, and responsive customer service that can answer analytical questions. Price per milligram is a secondary consideration to analytical quality for any research application where the data will be cited or built upon.

Open Research Questions

KPV's research profile, while substantive, leaves several important questions unresolved. These represent productive directions for future work.

MC1R-independence of anti-inflammatory effects: The partial persistence of KPV activity in MC1R-antagonized or MC1R-knockout systems suggests additional receptor interactions. Binding screens against the broader GPCR panel, formyl peptide receptors, or pattern recognition receptor co-receptors could clarify whether a secondary target exists. This is important because the pharmacological selectivity of KPV depends on the answer. 3

Oral bioavailability quantification: PepT1-mediated transport has been demonstrated in Caco-2 cells and inferred in mouse models, but no formal bioavailability study with absolute quantification of systemic KPV levels after oral dosing has been published. Given the short plasma half-life, the systemic contribution of orally absorbed KPV may be minimal; the relevant question may be mucosal tissue levels rather than plasma levels, requiring tissue homogenate LC-MS methods.

Formulation optimization for mucosal delivery: The nanoparticle encapsulation work from Dalmasso et al. demonstrated proof-of-concept for enhanced oral delivery, but the polymer system used (PLGA) represents one of many possible encapsulation strategies. Mucoadhesive polymers, lipid nanoparticles, and hydrogel-based systems have not been comparatively evaluated for KPV delivery. This is an active area in peptide delivery science broadly, and KPV is a candidate compound that warrants formal formulation optimization studies.

Comparison to pharmacological NF-kB inhibitors: KPV's NF-kB suppressive effect has not been benchmarked against established pharmacological NF-kB inhibitors (e.g., BAY 11-7082, parthenolide) in a head-to-head study in the same model system. Such a comparison would clarify whether KPV's NF-kB inhibition is quantitatively meaningful relative to tools already in use, or whether its primary research value lies in its selectivity and endogenous-origin profile rather than raw potency.

Long-term safety in continuous dosing models: All published animal studies are short-duration (days to weeks). Whether sustained NF-kB suppression by KPV produces immune tolerance, susceptibility to infection, or other off-target effects in chronic administration models has not been investigated. Any preclinical program aimed at therapeutic development would need to address this through 28-day or 90-day repeat-dose toxicology studies.